Literature DB >> 29537683

Predictors of adverse outcome in uterine smooth muscle tumours of uncertain malignant potential (STUMP): a clinicopathological analysis of 22 cases with a proposal for the inclusion of additional histological parameters.

Mamta Gupta1,2, Anna L Laury3, Marisa R Nucci2,4, Bradley J Quade2,4.   

Abstract

AIMS: The current World Health Organisation classification defines smooth muscle tumours of uncertain malignant potential (STUMPs) as neoplasms that cannot be diagnosed reliably as benign or malignant according to generally accepted criteria. This has led to the application of various sets of criteria; consequently, consistent and reliable outcome data are lacking. The aims of this study were: (i) to compare the frequency of adverse outcome in STUMP on the basis of enhanced criteria; and (ii) to perform failure analysis to identify feature(s) helpful in predicting outcome METHODS AND
RESULTS: Cases of STUMP diagnosed between 1994 and 2009 were retrieved and follow-up data were collected. Morphological parameters were scored and correlated with outcome. Twenty-two subjects with a median follow-up of 74.5 months (range, 26-166 months) formed the study group. Their age ranged from 31.9 years to 51.8 years (median, 45.3 years). Sixteen subjects underwent hysterectomy and six underwent myomectomy. Adverse outcomes were noted in eight (36.4%) cases. In cases with adverse outcomes, notable features included moderate-severe nuclear atypia (seven), epithelioid features (one), infiltrative or irregular margins (five), atypical mitoses (two), and vascular intrusion (three)
CONCLUSIONS: The frequency of adverse outcomes in our series (36.4%) was higher than that in previously published reports (7-26.7%), suggesting that the use of more stringent criteria can exclude some patients from further follow-up. Although 'significant' nuclear atypia was not discriminatory, its frequent association with adverse outcomes has pathobiological implications. The presence of necrosis was not particularly associated with adverse outcomes. Atypical mitoses, epithelioid differentiation, vascular involvement and infiltrative/irregular margins appear to herald adverse outcomes, and therefore merit inclusion in the diagnostic regimen.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990STUMPzzm321990; atypical leiomyoma; leiomyosarcoma; smooth muscle tumour of uncertain malignant potential; uterine leiomyoma

Mesh:

Year:  2018        PMID: 29537683     DOI: 10.1111/his.13515

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  10 in total

1.  Synergistic effects of pazopanib and hyperthermia against uterine leiomyosarcoma growth mediated by downregulation of histone acetyltransferase 1.

Authors:  Chiao-Yun Lin; Angel Chao; Ren-Chin Wu; Li-Yu Lee; Shir-Hwa Ueng; Chia-Lung Tsai; Yun-Shien Lee; Meng-Ting Peng; Lan-Yan Yang; Huei-Jean Huang; Hsin-Shih Wang; Chyong-Huey Lai
Journal:  J Mol Med (Berl)       Date:  2020-07-07       Impact factor: 4.599

2.  A novel morphology-based risk stratification model for stage I uterine leiomyosarcoma: an analysis of 203 cases.

Authors:  David B Chapel; Aarti Sharma; Ricardo R Lastra; Livia Maccio; Emma Bragantini; Gian Franco Zannoni; Suzanne George; Bradley J Quade; Carlos Parra-Herran; Marisa R Nucci
Journal:  Mod Pathol       Date:  2022-02-04       Impact factor: 7.842

3.  Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers.

Authors:  Fulvio Borella; Stefano Cosma; Domenico Ferraioli; Isabelle Ray-Coquard; Nicolas Chopin; Pierre Meeus; Vincent Cockenpot; Giorgio Valabrega; Giulia Scotto; Margherita Turinetto; Nicoletta Biglia; Luca Fuso; Luca Mariani; Dorella Franchi; Ailyn Mariela Vidal Urbinati; Ida Pino; Gianluca Bertschy; Mario Preti; Chiara Benedetto; Isabella Castellano; Paola Cassoni; Luca Bertero
Journal:  Ann Surg Oncol       Date:  2022-08-17       Impact factor: 4.339

Review 4.  Uterine fibroid-like tumors: spectrum of MR imaging findings and their differential diagnosis.

Authors:  Yenpo Lin; Ren-Chin Wu; Yen-Ling Huang; Kueian Chen; Shu-Chi Tseng; Chin-Jung Wang; Angel Chao; Chyong-Huey Lai; Gigin Lin
Journal:  Abdom Radiol (NY)       Date:  2022-03-26

5.  Oncologic and Reproductive Outcomes of Uterine Smooth Muscle Tumor of Uncertain Malignant Potential: A Single Center Retrospective Study of 67 Cases.

Authors:  Lanqing Huo; Dan Wang; Wenze Wang; Dongyan Cao; Jiaxin Yang; Ming Wu; Junjun Yang; Yang Xiang
Journal:  Front Oncol       Date:  2020-05-14       Impact factor: 6.244

Review 6.  The Usefulness of Immunohistochemistry in the Differential Diagnosis of Lesions Originating from the Myometrium.

Authors:  Piotr Rubisz; Michał Ciebiera; Lidia Hirnle; Magdalena Zgliczyńska; Tomasz Łoziński; Piotr Dzięgiel; Christopher Kobierzycki
Journal:  Int J Mol Sci       Date:  2019-03-06       Impact factor: 5.923

7.  Uterine smooth muscle tumour of uncertain malignant potential (STUMP): Where are we now?

Authors:  Raji Ganesan
Journal:  Case Rep Womens Health       Date:  2020-01-30

8.  Genomic and Epigenomic Profile of Uterine Smooth Muscle Tumors of Uncertain Malignant Potential (STUMPs) Revealed Similarities and Differences with Leiomyomas and Leiomyosarcomas.

Authors:  Donatella Conconi; Serena Redaelli; Andrea Alberto Lissoni; Chiara Cilibrasi; Patrizia Perego; Eugenio Gautiero; Elena Sala; Mariachiara Paderno; Leda Dalprà; Fabio Landoni; Marialuisa Lavitrano; Gaia Roversi; Angela Bentivegna
Journal:  Int J Mol Sci       Date:  2021-02-04       Impact factor: 5.923

9.  Clinical and reproductive outcomes of uterine smooth muscle tumor of uncertain malignant potential: a single-center retrospective study.

Authors:  Chengcheng Ning; Lihong Zhang; Chenyan Zhao; Xiaojun Chen; Xiaoxia Liu; Chao Gu
Journal:  J Int Med Res       Date:  2021-04       Impact factor: 1.671

10.  Intraparenchymal breast leiomyoma and atypical leiomyoma.

Authors:  Mengping Long; Xuejiao Lina Hu; Guiyang Zhao; Yiqiang Liu; Taobo Hu
Journal:  BMC Womens Health       Date:  2022-04-14       Impact factor: 2.809

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.